Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine
about
Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine ApproachInfluenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infectionSublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in miceImproving pandemic H5N1 influenza vaccines by combining different vaccine platforms.The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.Current and emerging cell culture manufacturing technologies for influenza vaccines.Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine.Nasal vaccine innovation.Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner.Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responsesInnate immune evasion strategies of influenza virusesSingle HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell cultureAn Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with InfectionNS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine.Principles underlying rational design of live attenuated influenza vaccines.Influenza viral vector based Brucella abortus vaccine: a novel vaccine candidate for veterinary practice.Mutations in the M-gene segment can substantially increase replication efficiency of NS1 deletion influenza A virus in MDCK cells.Avian influenza virus NS1: A small protein with diverse and versatile functions.
P2860
Q27316846-5705C0DB-9C8B-4E99-845A-CA849C68353FQ28658422-45DA68D2-EEBC-4B8F-B39C-5FC1E500A938Q28727930-9490A172-4CB0-4BEC-BC2E-6F900BA201E5Q30362811-C15DE366-B6A2-476B-B91E-6629BABC3AB1Q30372479-E0BA50B2-0722-4F94-992A-2B073242192EQ30373128-86D873C8-D889-4E5B-8AFA-8796DE77A7AEQ30378132-0598CB08-D825-4ACF-B545-FB413956D5B8Q30383973-E670B144-2991-482D-83D0-C5FE2F5127E0Q30385138-DCE064F9-4A67-4893-A518-BE305675528CQ30395810-D37AF491-3B30-426C-9F06-BA048A4FACCFQ30429058-B9000E85-C1B6-4CF4-897B-222E3772FF74Q30429134-DD45AAEB-7638-48D8-897C-0B7E111331E0Q33614507-D8F03083-9737-41B1-B751-38A66C443BFBQ33646273-95819382-06F3-408A-8E7D-7E08D9CC5A09Q33872175-7CD2A58F-7406-4ABD-A0E5-30A1EE27E3F3Q35363496-25D15835-DE76-41A5-8D64-06B27C6375D0Q36231510-61F952B8-420E-4EE7-B5C2-AE9182BB4F3FQ36276683-47DFDEF0-2710-4539-953B-84D146B6E498Q36482772-78C42F2F-7ADD-4E62-818F-28AFA113146BQ38627438-3A88249E-4B62-4C09-AF40-5EDE63E9974DQ39770895-6FA1C3F2-CBDE-4816-9BFB-F783AA71484BQ40631904-AB3524B9-58A6-4FB3-BFA3-7E15E90DE62DQ41573715-65EEAB4B-5B89-4F1E-AF6D-CC885A79B0AAQ42724653-BD4EC90E-5E2E-40CF-B26E-13E5B2ED94C1
P2860
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@ast
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@en
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@nl
type
label
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@ast
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@en
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@nl
prefLabel
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@ast
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@en
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@nl
P2093
P2860
P50
P1433
P1476
Preclinical evaluation of a re ...... eltaNS1 H5N1 influenza vaccine
@en
P2093
Alexander Mann
Alexander Morokutti
Andrej Egorov
Bettina Kiefmann
Brigitte M Krenn
Ekaterina Romanovskaja-Romanko
Markus Wolschek
Martin Slais
Michael Bergmann
Monika Sachet
P2860
P356
10.1371/JOURNAL.PONE.0005984
P407
P577
2009-01-01T00:00:00Z